carcinoma breast

Reading File

Finding Sources

Searching PubMed

"breast cancer" AND "management"

Reading File

Loading Image

I now have comprehensive material from the textbooks. Let me compile a thorough, well-organized answer.

Carcinoma of the Breast

Epidemiology

Breast cancer is the most common malignancy globally in females and the leading cause of cancer death in women worldwide. In 2020, it surpassed lung cancer as the most common cancer overall, accounting for ~12% of all new cancer diagnoses (an estimated 2.3 million new cases). The lifetime risk for an American woman is 1 in 8 (living to age 90).

75% of breast cancers are diagnosed after age 50
Incidence is highest in North America, Northern/Western Europe, and Australia/New Zealand
Overall risk of death from invasive breast cancer is ~20%, with gradual decline due to improved screening and adjuvant therapy
Females of African descent have the highest mortality rate, partly due to higher rates of biologically aggressive subtypes (e.g., TNBC)

Risk Factors

(Robbins, Cotran & Kumar Pathologic Basis of Disease)

Risk Factor	Relative Risk
Female sex, increasing age, germline high-penetrance mutations (BRCA1/2), strong family history, personal history of breast cancer, high breast density	>4.0
Germline moderate-penetrance mutations, high-dose chest radiation at <18 years, family history (1 first-degree relative)	2.1-4.0
Early menarche (<12 yrs), late menopause (>55 yrs), late first pregnancy (>35 yrs), nulliparity, no breastfeeding, exogenous hormone therapy, postmenopausal obesity, physical inactivity, high alcohol intake	1.1-2.0

~20% of breast cancers are attributable to modifiable risk factors (obesity, alcohol, physical inactivity).

Factors that decrease risk: Early first pregnancy (before age 20), prolonged breastfeeding, bilateral prophylactic mastectomy (~90% risk reduction), chemoprevention with ER antagonists (for high-risk women).

Genetic predisposition: ~12% of all breast cancers arise from germline mutations. BRCA1 and BRCA2 account for ~50% of single-gene mutation cases. Other high-risk genes include PALB2 and TP53.

Classification

1. Histological Classification

In Situ Carcinoma:

Ductal Carcinoma In Situ (DCIS): Precursor to invasive ductal carcinoma. Most often detected on mammography as microcalcifications. If untreated, progression leads to invasive ductal carcinoma in the same breast.
Lobular Carcinoma In Situ (LCIS): A marker of increased risk and a precursor lesion. When carcinoma subsequently develops, 2/3 are in the same breast and 1/3 in the contralateral breast.

Invasive Carcinoma:

The classic Foote-Stewart classification (Schwartz's Principles of Surgery):

Type	Frequency
Invasive ductal carcinoma, no special type (NST)	~80%
Invasive lobular carcinoma	~10%
Medullary carcinoma	~4%
Mucinous (colloid) carcinoma	~2%
Papillary carcinoma	~2%
Tubular carcinoma	~2%
Paget's disease of the nipple	Rare
Rare: adenoid cystic, squamous cell, apocrine	Rare

Invasive carcinoma of no special type (NST) - the most common subtype - typically presents as a hard, irregular, radiodense mass with a desmoplastic stromal reaction. When cut, it produces a characteristic grating sound.

Paget's disease of the nipple presents as chronic eczematous eruption of the nipple progressing to ulceration. Pathognomonic: large pale vacuolated Paget cells in the rete pegs. Differentiated from melanoma by carcinoembryonic antigen staining (vs. S-100 in melanoma).

2. Clinical Subtypes (Biomarker-Based) & Molecular Subtypes

Breast cancer classification by morphology, biomarkers, and gene expression

(Fig. 23.15 - Robbins, Cotran & Kumar Pathologic Basis of Disease)

Clinical Subtype	Biomarker Profile	Molecular Subtype	Frequency
Luminal	ER+/HER2- (low proliferation)	Luminal A	35-45%
Luminal	ER+/HER2- (high proliferation)	Luminal B	20-25%
HER2	HER2+ (ER+/- )	HER2-enriched	~20%
Triple Negative (TNBC)	ER-/PR-/HER2-	Basal-like	~15%

Key molecular subtype features:

Luminal A: Low grade, ER-positive, best prognosis, responds to endocrine therapy
Luminal B: Higher proliferation, worse prognosis than A
HER2-enriched: HER2 gene amplification/overexpression; responds to HER2-targeted therapy (trastuzumab, pertuzumab); high proliferation, often ER-negative
TNBC/Basal-like: Associated with BRCA1 mutations and TP53 mutations; high-grade, most aggressive, poorest prognosis; only systemic option was chemotherapy (immunotherapy now plays a role)

Pathogenesis

Two major pathways (Robbins, Cotran & Kumar):

Low-grade pathway (ER-positive): Columnar cell lesions → flat epithelial atypia → atypical ductal/lobular hyperplasia → low-grade DCIS / classic LCIS → low-grade invasive carcinoma. Genetically defined by loss of 16q.

High-grade pathway (ER-negative/TNBC): Often driven by BRCA1 loss-of-function and TP53 mutations. High-grade DCIS → high-grade invasive carcinoma.

Histological Grading (Nottingham Score)

All invasive carcinomas are graded by:

Tubule/gland formation
Nuclear pleomorphism
Mitotic rate

Grade 1 (well differentiated): Tubular/cribriform pattern, small uniform nuclei, low mitotic rate
Grade 2 (moderately differentiated): Solid clusters or single cells, greater nuclear pleomorphism, more mitoses
Grade 3 (poorly differentiated): Ragged nests/sheets, enlarged irregular nuclei, high mitotic rate, frequent necrosis

Clinical Features

Painless breast lump (most common presentation)
Skin dimpling or retraction (due to involvement of Cooper's ligaments)
Nipple retraction or discharge
Peau d'orange appearance (lymphedema of skin)
Axillary lymphadenopathy
In inflammatory breast carcinoma: warm, erythematous, edematous breast with rapid onset - a clinical diagnosis

Diagnosis

Triple assessment:

Clinical: History and physical examination
Imaging: Mammography (principal screening tool), ultrasound (especially useful in young/dense breasts and axillary staging), MRI for high-risk screening
Pathology: Fine needle aspiration (FNA), core needle biopsy (preferred - provides histology + receptor status)

Mammographic signs of malignancy:

Spiculated/irregular mass
Asymmetric density/architectural distortion
Clustered microcalcifications (especially in DCIS)

Biomarker testing on all invasive cancers:

ER and PR (immunohistochemistry)
HER2 (IHC + FISH for gene amplification)
Ki-67 (proliferation index)
Gene expression assays (Oncotype DX, MammaPrint) to guide adjuvant chemotherapy decisions in certain ER+/HER2- cases

Staging (AJCC 8th Edition TNM)

The 8th edition uniquely incorporates both anatomic stage and biologic factors (ER, PR, HER2, grade, Oncotype DX score) to create prognostic stage groups.

T - Primary Tumor:

TX: Cannot assess
T0: No evidence
Tis: In situ (DCIS or Paget's without invasive tumor)
T1: ≤2 cm (T1mi ≤0.1 cm, T1a >0.1-0.5 cm, T1b >0.5-1 cm, T1c >1-2 cm)
T2: >2-5 cm
T3: >5 cm
T4: Any size with chest wall or skin involvement (T4d = inflammatory carcinoma)

N - Regional Lymph Nodes:

N0: No regional node metastasis
N1: Movable ipsilateral axillary nodes (level I/II)
N2: Fixed ipsilateral axillary nodes OR internal mammary nodes without axillary
N3: Ipsilateral infraclavicular (level III) / supraclavicular / internal mammary + axillary

M - Distant Metastasis:

M0: No distant metastasis
M1: Distant metastasis (bone, liver, lung, brain commonest)

Overall Stage Groups: Stage 0 to IV. Number of positive axillary lymph nodes is one of the most important predictors of 10- and 20-year survival.

Surgical Management

Breast Surgery Options

Breast-conserving surgery (BCS/lumpectomy): Wide local excision + radiation therapy; equivalent survival to mastectomy for appropriate candidates (tumor <4-5 cm, favorable tumor-to-breast ratio, no multicentric disease, no contraindication to radiotherapy)
Mastectomy: Simple/total, modified radical (with axillary dissection), skin/nipple-sparing for reconstruction candidates
Oncoplastic techniques: Combine resection and immediate reconstruction

Axillary Staging

Sentinel lymph node biopsy (SLNB): Standard for clinically node-negative patients; avoids full axillary clearance and its morbidity (lymphedema)
Axillary lymph node dissection (ALND): For positive sentinel nodes (per institutional/clinical trial criteria), clinically node-positive, or when SLNB not feasible

Systemic Treatment

Adjuvant Chemotherapy

Used in: HER2+, TNBC, high-grade luminal B, high-risk luminal cancers
Common regimens: AC (doxorubicin + cyclophosphamide) → Taxane (paclitaxel/docetaxel)
Gene expression assays (Oncotype DX Recurrence Score) guide chemotherapy decisions in ER+/HER2-/node-negative patients

Endocrine Therapy

For ER+ and/or PR+ tumors (all subtypes)
Premenopausal: Tamoxifen (SERM) ± ovarian suppression for 5-10 years; aromatase inhibitors (AIs) + ovarian suppression for high-risk
Postmenopausal: Aromatase inhibitors (anastrozole, letrozole, exemestane) preferred over tamoxifen; extended therapy (up to 10 years) for high-risk disease
CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) + AI for metastatic ER+/HER2- disease, and abemaciclib now approved adjuvantly in high-risk early breast cancer

Anti-HER2 Therapy

Trastuzumab (Herceptin): Monoclonal antibody against HER2; adjuvant + neoadjuvant; combined with chemotherapy
Pertuzumab: Combined with trastuzumab + docetaxel (neoadjuvant/metastatic)
T-DM1 (ado-trastuzumab emtansine): Antibody-drug conjugate for residual disease after neoadjuvant therapy
Lapatinib, neratinib, tucatinib: Oral HER2-targeted tyrosine kinase inhibitors

TNBC Treatment

Chemotherapy remains backbone
Immunotherapy: Pembrolizumab (anti-PD-1) + chemotherapy for PD-L1 positive metastatic TNBC and for early high-risk TNBC (neoadjuvant)
PARP inhibitors (olaparib, talazoparib): For BRCA1/2 mutant HER2-negative metastatic breast cancer
Antibody-drug conjugates: Sacituzumab govitecan (anti-Trop-2) for metastatic TNBC

Radiation Therapy

After BCS: Whole-breast irradiation ± boost to tumor bed (standard)
Post-mastectomy radiation (PMRT): For ≥4 positive nodes, T3/T4 tumors, positive margins
Regional nodal irradiation for node-positive disease

Neoadjuvant Therapy

Allows tumor downstaging for BCS eligibility
Pathologic complete response (pCR) is a surrogate for improved outcomes
HER2+ and TNBC show highest pCR rates
Enables tailoring of adjuvant therapy based on residual disease

Prognosis

Prognosis depends on:

Biologic subtype - Luminal A best; TNBC worst
Anatomic stage - Tumor size and nodal status
Grade
Response to treatment

Luminal cancers show a prolonged risk of late recurrence (beyond 5 years), while TNBCs recur early. HER2 cancers, once the worst prognosis group, have been transformed by targeted therapy.

The AJCC 8th edition prognostic stage groups combine anatomic and biologic factors, providing more accurate survival estimates than anatomy alone.

Sources:

Robbins & Kumar Basic Pathology, Ch. on Breast Carcinoma
Robbins, Cotran & Kumar Pathologic Basis of Disease, Ch. 23 (Breast)
Schwartz's Principles of Surgery, 11th Ed., Ch. 17 (Breast)
Bailey and Love's Short Practice of Surgery, 28th Ed., Ch. on Breast

tubercular peritonitis

Reading File

Finding Sources

Searching PubMed

"tuberculous peritonitis" AND diagnosis

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

I now have comprehensive, well-sourced content from five textbooks. Let me compile the full answer.

Tubercular (Tuberculous) Peritonitis

Definition and Overview

Tuberculous peritonitis (TBP) is a form of extrapulmonary tuberculosis involving the peritoneal cavity, caused by Mycobacterium tuberculosis. It is the sixth most common site of extrapulmonary TB, accounting for 0.5% of new TB cases. The abdomen is involved in approximately 11% of patients with extrapulmonary TB overall. The condition is common in resource-poor countries but its incidence is rising in resource-rich nations due to migration, HIV co-infection, and immunosuppression.

Pathogenesis / Routes of Spread

TB reaches the peritoneum by four main routes (Bailey and Love, 28th Ed.):

Gastrointestinal tract - through the ileocaecal region (the most common GI site of abdominal TB) via mesenteric lymph nodes
Haematogenous spread - from miliary TB (most common) or cavitating pulmonary TB
Lymphatic spread - from involved retroperitoneal or mesenteric nodes
Direct spread - from the Fallopian tubes (in women)

50-80% of patients with abdominal TB have peritoneal involvement.

Important: Active pulmonary TB is uncommon in patients with TBP - only about one-third have clinical or radiographic evidence of pulmonary disease. (Frameworks for Internal Medicine)

Pathological Types (Morphological Classification)

(Bailey and Love)

Type	Features	Frequency
Wet (Ascitic) type	Generalised or loculated ascites; multiple tubercle deposits on both peritoneal layers	~90% (most common)
Dry (Plastic/Fibrotic) type	Fibrotic fixed loops of bowel and omentum matted together; no ascites; may cause subacute intestinal obstruction	Less common
Mixed type	Features of both wet and dry forms	Less common

The dry type typically presents with intestinal obstruction rather than ascites, and can be clinically indistinguishable from carcinomatosis or Crohn's disease.

Risk Factors

HIV co-infection (most significant immunosuppressive risk)
Liver cirrhosis (ascites masks TB symptoms; also reduces host immune response)
Diabetes mellitus
Underlying malignancy
Chronic renal failure / peritoneal dialysis
Immunosuppressive therapy
Residence in or migration from endemic countries

Clinical Features

Presentation is typically insidious, with symptoms present for weeks to months before diagnosis. (Yamada's Textbook of Gastroenterology)

Systemic symptoms (constitutional):

Low-grade fever and night sweats
Weight loss and anorexia
Malaise and fatigue

Abdominal symptoms:

Abdominal pain (most common presenting symptom) - often diffuse and dull
Abdominal distension / swelling (due to ascites)
Abdominal tenderness - present in less than half of patients

Other features:

Doughy feel of the abdomen (due to omental thickening and matted bowel loops)
Features of intestinal obstruction (in fibrotic/dry type)
Acute presentation resembling bacterial peritonitis (rare but occurs)

Note: The co-existence of TBP with cirrhosis is particularly deceptive - TB symptoms may be completely masked by the underlying liver disease. A high index of suspicion is needed in any patient with ascites + fever + abdominal tenderness. (Murray & Nadel's)

Diagnosis

1. Ascitic Fluid Analysis (Paracentesis)

This is the first-line investigation. Key characteristics:

Parameter	Finding in TBP
Appearance	Straw-coloured exudate
Protein	>25-30 g/L (>3 g/dL) - exudative
WBC count	>500 cells/mL (typically 50-10,000 leukocytes/µL)
Cell differential	Lymphocytic predominance (>40-70%)
SAAG	Low (<1.1 g/dL) in non-cirrhotic patients
Glucose	Low
AFB smear	Positive in <3% of cases
AFB culture	Positive in ~40-50%; takes 4-8 weeks

SAAG caveat: In cirrhotic patients with TBP, the SAAG may be high (>1.1 g/dL) due to concurrent portal hypertension, making the diagnosis even harder. (Yamada's)

Lymphocytic ascites differential: Cancer causes lymphocytic ascites ~10 times more often than TB. Key distinguishing feature: if peritoneal carcinomatosis is present, cytology is positive in >90% of cases. If cytology is negative and fever is present, TB is the likely diagnosis. (Sleisenger & Fordtran's; Yamada's)

2. Adenosine Deaminase (ADA) in Ascitic Fluid

This is the most useful rapid, non-invasive diagnostic test.

ADA sensitivity: 100%, specificity: 97% (meta-analysis of 12 studies, n=264 patients)
Optimal cut-off: 39 IU/L (range 36-40 IU/L used across studies)
High sensitivity and specificity for differentiating TBP from peritoneal carcinomatosis
Limitations:
- False negatives in HIV co-infection and cirrhosis
- False positives in malignant ascites
Recommended in all cases of suspected TBP given diagnostic accuracy and wide availability (Yamada's)

(Murray & Nadel's confirms: ADA sensitivity 93%, specificity 96% for TBP)

3. Molecular Tests

Xpert MTB/RIF (GeneXpert PCR): Rapid molecular test; highly sensitive and specific for M. tuberculosis in ascitic fluid; provides results in hours and detects rifampicin resistance
PCR for MTB: Highly sensitive and specific; results in days vs. weeks for culture (Frameworks for Internal Medicine)
ELISPOT: Novel, rapid, immunological test - detects interferon-gamma release (Sleisenger & Fordtran's)
Serum QuantiFERON-TB Gold: Poor test characteristics for diagnosing active TBP, especially in TB-endemic countries with BCG vaccination (Sleisenger & Fordtran's)

4. Imaging

Ultrasonography / CT abdomen:
- Detection of free or loculated ascites
- Lymphadenopathy (mesenteric/retroperitoneal)
- Diffuse thickening of peritoneum, mesentery, and omentum
- "Omental caking" can mimic malignancy
- TBP may appear as a pelvic mass with elevated CA-125, closely mimicking metastatic ovarian cancer (Sleisenger & Fordtran's)
Chest X-ray / CT chest: To detect concurrent pulmonary TB (present in ~30%)

5. Laparoscopy + Peritoneal Biopsy

The gold-standard investigation. (Yamada's)

Near 100% sensitivity for detecting TBP
Characteristic macroscopic appearances: scattered whitish/miliary peritoneal nodules (tubercles), thickened peritoneum
All nodules should be biopsied
Histology: Caseating granulomas in >90% of cases
Allows simultaneous culture of biopsy tissue
Should be performed at an early stage whenever TBP is suspected and non-invasive tests are inconclusive

Summary of diagnostic algorithm:

Paracentesis → ascitic fluid analysis (protein, SAAG, cell count, cytology, ADA, AFB smear + culture)
If cytology positive → peritoneal carcinomatosis diagnosis made
If cytology negative + fever + lymphocytic ascites → proceed to ADA / Xpert MTB/RIF
If still inconclusive → laparoscopy + peritoneal biopsy

Differential Diagnosis

Peritoneal carcinomatosis (most important - especially ovarian, GI malignancy)
Spontaneous bacterial peritonitis (in cirrhosis)
Cirrhotic ascites
Fat necrosis of pancreatitis (caseating nodules can mimic)
Mesothelioma
Familial Mediterranean fever
Other granulomatous peritonitis (fungal, sarcoidosis, Crohn's disease)

Treatment

Anti-TB Drug Regimen

(Consistent across Sleisenger & Fordtran's, Yamada's, and Bailey and Love)

Standard 6-month regimen:

Phase	Duration	Drugs
Intensive phase	8 weeks (2 months)	Isoniazid (H) + Rifampicin (R) + Pyrazinamide (Z) + Ethambutol (E) → 2HRZE
Continuation phase	16 weeks (4 months)	Isoniazid (H) + Rifampicin (R) → 4HR

Total duration: 6 months for uncomplicated TBP
May be extended to 9-12 months depending on local drug susceptibility patterns and emergence of resistant strains
Multi-drug resistant TB (MDR-TB) may be more common in abdominal than pulmonary TB - drug susceptibility testing is essential
All treatment must be directly observed (DOT) by public health/clinical staff - erratic treatment leads to resistance

Special situations:

Cirrhotic patients: Hepatotoxicity of first-line drugs (isoniazid, rifampicin, pyrazinamide) may necessitate modification of regimen - requires careful monitoring of LFTs
HIV co-infection: Manage with specialist involvement; rifampicin interactions with antiretrovirals require attention

Supportive Management

Nutritional support and hydration
Corticosteroids: Controversial; may be considered in severely symptomatic or complications cases to reduce inflammation - evidence limited

Surgical Management

Surgery is not primary but may be required for complications:

Intestinal obstruction (may respond to anti-TB treatment without surgery first)
Bowel perforation
Fistula formation
Abscesses not responding to medical therapy

Prognosis

Generally good with prompt diagnosis and appropriate treatment
Delayed diagnosis significantly increases morbidity and mortality
Late diagnosis is common due to the insidious nature and frequent absence of pulmonary TB
Complications (intestinal obstruction, adhesions) may persist even after successful treatment of infection

Sources:

Bailey and Love's Short Practice of Surgery, 28th Ed. - Ch. 65 (Peritoneum)
Sleisenger and Fordtran's Gastrointestinal and Liver Disease - Tuberculous Peritonitis
Yamada's Textbook of Gastroenterology, 7th Ed. - Evaluation of Peritoneal Tuberculosis
Murray & Nadel's Textbook of Respiratory Medicine - Peritoneal Tuberculosis
Frameworks for Internal Medicine - Peritoneal Tuberculosis Diagnostics

This is a shared conversation. Sign in to Orris to start your own chat.